Big Pharma faces $26.5B in losses this year as next big patent cliff looms, analyst says

Big Pharma faces $26.5B in losses this year as next big patent cliff looms, analyst says

Friday, April 21, 2017

With $26.5 billion in cumulative sales at risk, several big-selling meds from some of the world’s top drugmakers face a patent expiry this year, according to Bernstein’s Tim Anderson, who’s warning of a “patent cliff 2.0.”